Kidswell Bio Corporation
Stock Price Chart
2026/10/09 19:27 UpdatedPrice Trend
2026/10/09 19:27 UpdatedPrice & Trading Details
2026/10/09 19:27 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/10/01Shareholder Composition
Updated 2026/10/01Financial Performance
2026/10/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥2,776M | ¥2,431M | ¥5,082M | ¥6,590M |
| Gross Profit | ¥1,526M | ¥1,039M | ¥1,640M | ¥1,747M |
| Operating Income | -¥551M | -¥1,336M | ¥28M | -¥139M |
| Pretax Income | -¥621M | -¥1,382M | ¥115M | -¥354M |
| Net Income | -¥657M | -¥1,422M | -¥21M | -¥414M |
| EPS | -¥20.77 | -¥40.23 | -¥0.52 | -¥8.48 |
| Operating Margin | -19.84% | -54.93% | 0.55% | -2.10% |
| Balance Sheet | ||||
| Total Assets | ¥3,895M | ¥5,086M | ¥7,008M | ¥6,088M |
| Total Equity | ¥1,234M | ¥831M | ¥1,411M | ¥1,654M |
| Total Liabilities | ¥2,661M | ¥4,254M | ¥5,598M | ¥4,434M |
| Cash | ¥1,067M | ¥2,231M | ¥2,995M | ¥3,295M |
| Interest-bearing Debt | ¥1,950M | ¥2,575M | ¥1,838M | ¥2,550M |
| Equity Ratio | 31.67% | 16.35% | 20.13% | 27.17% |
| D/E Ratio | 1.58 | 3.10 | 1.30 | 1.54 |
| Cash Flow | ||||
| Operating CF | -¥1,421M | -¥454M | ¥937M | -¥1,096M |
| Investing CF | -¥29M | - | ¥65M | -¥13M |
| Financing CF | ¥1,356M | ¥1,618M | -¥240M | ¥1,398M |
| Free CF | -¥1,421M | -¥454M | ¥930M | -¥1,114M |
| Efficiency | ||||
| ROE | -53.30% | -171.03% | -1.50% | -25.03% |
| ROA | -16.88% | -27.96% | -0.30% | -6.80% |
Latest IR Information
-
Notice Regarding Recording of Special Profit (Sell-off of Investment Securities)
Plans to sell a portion of investment securities and record 221,717 thousand yen as special profit. Sale period from September 1 to 18, 2026. Special profit to be recorded in the second quarter of the fiscal year ending March 2027....
Read more -
Issuance Details of Stock-based Compensation Stock Options (New Stock Acquisition Rights)
Issuance details of new stock acquisition rights are finalized. For the 27th and 28th grants, a total of 3 directors and 3 auditors, plus 27 employees, were allocated, with 213 and 947 rights respectively; ordinary shares allocated: 21,300 shares and...
Read more -
FY2026 Q1 Financial Results Supplementary Explanation Materials
FY2026 Q1 earnings supplement. Includes year-over-year comparisons of net sales and key profit indicators, segment trends, and full-year guidance; focuses on detailed financial data and future outlook.
Read more -
Notice on Recording of Non-operating Expenses
For the first quarter of the fiscal year ending March 2027 (consolidated cumulative period from 2026/4/1 to 2026/6/30), interest expense of 22,864 thousand yen has been recorded as a non-operating expense. See the earnings release for the period for details...
Read more -
Q1 FY2027 Financial Summary (Japan GAAP) (Consolidated)
For the first quarter of FY2027, net sales were 1,269 million yen, down 26.2% year over year. Operating income was 216 million yen, ordinary income 203 million yen, and net income attributable to owners of the parent 197.9 million yen....
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥450
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company also offers GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Chuo, Japan.
